Skip to content

Study · Randomized controlled trial · n = 10 · 2000

7 results

Effect of an alpha-melanocyte stimulating hormone analog on penile erection and sexual desire in men with organic erectile dysfunction.

Wessells H, Gralnek D, Dorr R, Hruby VJ, Hadley ME, Levine N

Urology1 Oct 2000Cited by 98 (Europe PMC)

PMID11018622 (opens in a new tab)DOI10.1016/s0090-4295(00)00680-4 (opens in a new tab)PepBankPUB-11018622
Publisher pagePubMedAsk about this study
Jump to 7 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study7

7 results from studies that gave the peptide. 7 results from people.

  1. 01HumanRandomized controlled trialEfficacy outcome

    In men with organic erectile dysfunction, Melanotan II initiated subjectively reported erections in 12 of 19 injections versus 1 of 21 placebo doses.

    In plain wordsIn men with erectile dysfunction, Melanotan II led to reported erections after 12 of 19 injections, compared with 1 of 21 placebo doses.

    Peptide
    Melanotan II
    Outcome
    IncreaseSubjectively reported erections
    Study

    n = 10

    Comparator
    Placebo (vehicle)
    Outcome group
    Sexual function · Reproductive and sexual health
    Studied dose
    0.025 mg/kg · subcutaneousAs given in this study (human).

    Measurements

    injections with reported erection
    12 of 19 injections
    Melanotan II
    doses with reported erection
    1 of 21 doses
    placebo

    Source sentences

    Summary
    Melanotan II initiated subjectively reported erections in 12 of 19 injections versus only 1 of 21 doses of placebo.
    3 context sentences
    Summary · context
    To assess the safety, erectogenic properties, and effect on sexual desire of Melanotan II, a synthetic melanotropic initiator of erection, in men with erectile dysfunction and organic risk factors.
    Summary · context
    Ten subjects were enrolled in a double-blind, placebo-controlled, crossover study.
    Summary · context
    Melanotan II (0.025 mg/kg) and vehicle were each administered twice by subcutaneous injection; real-time RigiScan monitoring and a visual analog were used to quantify the erections during a 6-hour period.
  2. 02HumanRandomized controlled trialEfficacy outcome

    In men with organic erectile dysfunction, Melanotan II increased the mean duration of tip rigidity above 80% to 45.3 minutes versus 1.9 minutes with placebo.

    In plain wordsIn men with erectile dysfunction, Melanotan II gave longer firm erections than placebo (45.3 minutes versus 1.9 minutes).

    Peptide
    Melanotan II
    Outcome
    IncreaseDuration of tip rigidity above 80%
    Study

    n = 10

    Comparator
    Placebo (vehicle)
    Outcome group
    Sexual function · Reproductive and sexual health
    Studied dose
    0.025 mg/kg · subcutaneousAs given in this study (human).

    Measurements

    mean duration of tip rigidity >80%
    45.3 minutes
    Melanotan II
    mean duration of tip rigidity >80%
    1.9 minutes
    placebo
    P value
    0.047
    between groups

    Source sentences

    Summary
    The mean duration of tip rigidity greater than 80% was 45.3 minutes with Melanotan II versus 1.9 for placebo (P = 0.047).
    3 context sentences
    Summary · context
    To assess the safety, erectogenic properties, and effect on sexual desire of Melanotan II, a synthetic melanotropic initiator of erection, in men with erectile dysfunction and organic risk factors.
    Summary · context
    Ten subjects were enrolled in a double-blind, placebo-controlled, crossover study.
    Summary · context
    Melanotan II (0.025 mg/kg) and vehicle were each administered twice by subcutaneous injection; real-time RigiScan monitoring and a visual analog were used to quantify the erections during a 6-hour period.
  3. 03HumanRandomized controlled trialEfficacy outcome

    In men with organic erectile dysfunction, sexual desire after injection was significantly higher after Melanotan II than after placebo.

    In plain wordsIn men with erectile dysfunction, sexual desire was higher after Melanotan II than after placebo.

    Peptide
    Melanotan II
    Outcome
    IncreaseSexual desire after injection
    Study

    n = 10

    Comparator
    Placebo (vehicle)
    Outcome group
    Sexual function · Reproductive and sexual health
    Studied dose
    0.025 mg/kg · subcutaneousAs given in this study (human).

    Source sentences

    Summary
    The level of sexual desire after injection was significantly higher after Melanotan II administration than after placebo.
    3 context sentences
    Summary · context
    To assess the safety, erectogenic properties, and effect on sexual desire of Melanotan II, a synthetic melanotropic initiator of erection, in men with erectile dysfunction and organic risk factors.
    Summary · context
    Ten subjects were enrolled in a double-blind, placebo-controlled, crossover study.
    Summary · context
    Melanotan II (0.025 mg/kg) and vehicle were each administered twice by subcutaneous injection; real-time RigiScan monitoring and a visual analog were used to quantify the erections during a 6-hour period.
  4. 04HumanRandomized controlled trialSafety outcome

    In men with organic erectile dysfunction, nausea occurred more frequently with Melanotan II than with placebo.

    In plain wordsIn men with erectile dysfunction, nausea happened more often with Melanotan II than with placebo.

    Peptide
    Melanotan II
    Outcome
    IncreaseNausea
    Study

    n = 10

    Comparator
    Placebo (vehicle)
    Outcome group
    Gastrointestinal adverse events · Gastrointestinal
    Studied dose
    0.025 mg/kg · subcutaneousAs given in this study (human).

    Source sentences

    Summary
    Nausea and stretching/yawning occurred more frequently with Melanotan II, and 4 of 19 injections were associated with severe nausea.
    3 context sentences
    Summary · context
    To assess the safety, erectogenic properties, and effect on sexual desire of Melanotan II, a synthetic melanotropic initiator of erection, in men with erectile dysfunction and organic risk factors.
    Summary · context
    Ten subjects were enrolled in a double-blind, placebo-controlled, crossover study.
    Summary · context
    Melanotan II (0.025 mg/kg) and vehicle were each administered twice by subcutaneous injection; real-time RigiScan monitoring and a visual analog were used to quantify the erections during a 6-hour period.
  5. 05HumanRandomized controlled trialSafety outcome

    In men with organic erectile dysfunction, stretching and yawning occurred more frequently with Melanotan II than with placebo.

    In plain wordsIn men with erectile dysfunction, stretching and yawning happened more often with Melanotan II than with placebo.

    Peptide
    Melanotan II
    Outcome
    IncreaseStretching and yawning
    Study

    n = 10

    Comparator
    Placebo (vehicle)
    Outcome group
    Adverse events · Whole body
    Studied dose
    0.025 mg/kg · subcutaneousAs given in this study (human).

    Source sentences

    Summary
    Nausea and stretching/yawning occurred more frequently with Melanotan II, and 4 of 19 injections were associated with severe nausea.
    3 context sentences
    Summary · context
    To assess the safety, erectogenic properties, and effect on sexual desire of Melanotan II, a synthetic melanotropic initiator of erection, in men with erectile dysfunction and organic risk factors.
    Summary · context
    Ten subjects were enrolled in a double-blind, placebo-controlled, crossover study.
    Summary · context
    Melanotan II (0.025 mg/kg) and vehicle were each administered twice by subcutaneous injection; real-time RigiScan monitoring and a visual analog were used to quantify the erections during a 6-hour period.
  6. 06HumanRandomized controlled trialSafety outcome

    In men with organic erectile dysfunction, 4 of 19 Melanotan II injections were associated with severe nausea.

    In plain wordsIn men with erectile dysfunction, 4 of 19 Melanotan II injections were linked to severe nausea.

    Peptide
    Melanotan II
    Outcome
    Not applicableSevere nausea
    Study

    n = 10

    Outcome group
    Gastrointestinal adverse events · Gastrointestinal
    Studied dose
    0.025 mg/kg · subcutaneousAs given in this study (human).

    Measurements

    injections with severe nausea
    4 of 19 injections
    Melanotan II

    Source sentences

    Summary
    4 of 19 injections were associated with severe nausea.
    3 context sentences
    Summary · context
    To assess the safety, erectogenic properties, and effect on sexual desire of Melanotan II, a synthetic melanotropic initiator of erection, in men with erectile dysfunction and organic risk factors.
    Summary · context
    Ten subjects were enrolled in a double-blind, placebo-controlled, crossover study.
    Summary · context
    Melanotan II (0.025 mg/kg) and vehicle were each administered twice by subcutaneous injection; real-time RigiScan monitoring and a visual analog were used to quantify the erections during a 6-hour period.
  7. 07HumanRandomized controlled trialEfficacy outcome

    In men with organic erectile dysfunction, the mean rigidity score of responders to Melanotan II was 6.9 on a scale of 0 to 10.

    In plain wordsIn men with erectile dysfunction who responded to Melanotan II, the mean rigidity score was 6.9 on a scale of 0 to 10.

    Peptide
    Melanotan II
    Outcome
    Not applicableRigidity score of responders
    Study

    n: not reported in source

    Outcome group
    Sexual function · Reproductive and sexual health
    Studied dose
    0.025 mg/kg · subcutaneousAs given in this study (human).

    Measurements

    mean rigidity score
    6.9 scale 0-10
    responders

    Source sentences

    Summary
    The mean rigidity score of the responders was 6.9 on a scale of 0 to 10.
    3 context sentences
    Summary · context
    To assess the safety, erectogenic properties, and effect on sexual desire of Melanotan II, a synthetic melanotropic initiator of erection, in men with erectile dysfunction and organic risk factors.
    Summary · context
    Ten subjects were enrolled in a double-blind, placebo-controlled, crossover study.
    Summary · context
    Melanotan II (0.025 mg/kg) and vehicle were each administered twice by subcutaneous injection; real-time RigiScan monitoring and a visual analog were used to quantify the erections during a 6-hour period.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    9 Oct 2026, 18:17 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 03:04 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.